电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

CD226 抗体 (Ser329)

This 兔 多克隆 anti-CD226 antibody specifically detects CD226 in WB, ELISA, IHC 和 IF/ICC. The antibody is reactive with 人, 小鼠 和 猴 samples.
产品编号 ABIN6102395
发货至: 中国
Contact our Customer Service for availability and price in your country. Contact Info

Our Local Distributor

中国
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
4A Biotech Co.,Ltd.
Tel +86 (0512) 65829739 传真 +86 (010) 6788 5057

Quick Overview for CD226 抗体 (Ser329) (ABIN6102395)

抗原

See all CD226 抗体
CD226

适用

  • 86
  • 35
  • 5
  • 4
  • 2
  • 1
  • 1
人, 小鼠, 猴

宿主

  • 65
  • 35
  • 10
  • 2

克隆类型

  • 61
  • 50
  • 1
多克隆

标记

  • 58
  • 11
  • 7
  • 7
  • 7
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
This CD226 antibody is un-conjugated

应用范围

  • 54
  • 42
  • 32
  • 26
  • 25
  • 15
  • 9
  • 4
  • 3
  • 1
  • 1
  • 1
  • 1
Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunofluorescence (fixed cells) (IF/ICC)
  • 抗原表位

    • 11
    • 10
    • 8
    • 7
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Ser329

    纯化方法

    Affinity Chromatography

    免疫原

    Synthesized peptide derived from human DNAM-1 around the non-phosphorylation site of S329.

    亚型

    IgG
  • 应用备注

    Optimal working dilution should be determined by the investigator.

    限制

    仅限研究用
  • 状态

    Liquid

    缓冲液

    PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.

    储存液

    Sodium azide

    注意事项

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    储存条件

    -20 °C,-80 °C

    储存方法

    Aliquot and store at -20 °C or -80 °C. Avoid repeated freeze/thaw cycles.
  • 抗原

    CD226

    别名

    CD226

    基因ID

    10666

    UniProt

    Q15762

    途径

    Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
You are here: